-
Something wrong with this record ?
Human Multipotent Mesenchymal Stromal Cells in the Treatment of Postoperative Temporal Bone Defect: An Animal Model
L. Skoloudik, V. Chrobok, D. Kalfert, Z. Koci, E. Sykova, T. Chumak, J. Popelar, J. Syka, J. Laco, J. Dedková, G. Dayanithi, S. Filip,
Language English Country United States
Document type Journal Article, Research Support, Non-U.S. Gov't
NLK
ProQuest Central
from 2016-01-01
Health & Medicine (ProQuest)
from 2016-01-01
ROAD: Directory of Open Access Scholarly Resources
from 1992
- MeSH
- Biomarkers metabolism MeSH
- Humans MeSH
- Mesenchymal Stem Cells cytology MeSH
- Disease Models, Animal MeSH
- Guinea Pigs MeSH
- Multipotent Stem Cells cytology MeSH
- Tomography, X-Ray Computed MeSH
- Postoperative Care * MeSH
- Temporal Bone diagnostic imaging pathology surgery MeSH
- Mesenchymal Stem Cell Transplantation * MeSH
- Ear, Inner pathology MeSH
- Inflammation pathology MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Guinea Pigs MeSH
- Male MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Canal wall down mastoidectomy is one of the most effective treatments for cholesteatoma. However, it results in anatomical changes in the external and middle ear with a negative impact on the patient's quality of life. To provide complete closure of the mastoid cavity and normalize the anatomy of the middle and external ear, we used human multipotent mesenchymal stromal cells (hMSCs), GMP grade, in a guinea pig model. A method for preparing a biomaterial composed of hMSCs, hydroxyapatite, and tissue glue was developed. Animals from the treated group were implanted with biomaterial composed of hydroxyapatite and hMSCs, while animals in the control group received hydroxyapatite alone. When compared to controls, the group implanted with hMSCs showed a significantly higher ratio of new bone formation (p = 0.00174), as well as a significantly higher volume percentage of new immature bone (p = 0.00166). Our results proved a beneficial effect of hMSCs on temporal bone formation and provided a promising tool to improve the quality of life of patients after canal wall down mastoidectomy by hMSC implantation.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17014236
- 003
- CZ-PrNML
- 005
- 20170427111145.0
- 007
- ta
- 008
- 170413s2016 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3727/096368915X689730 $2 doi
- 035 __
- $a (PubMed)26497735
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Skoloudik, Lukas $u Department of Otorhinolaryngology and Head and Neck Surgery, University Hospital Hradec Kralové, Charles University in Prague, Faculty of Medicine in Hradec Kralové, Hradec Kralové, Czech Republic.
- 245 10
- $a Human Multipotent Mesenchymal Stromal Cells in the Treatment of Postoperative Temporal Bone Defect: An Animal Model / $c L. Skoloudik, V. Chrobok, D. Kalfert, Z. Koci, E. Sykova, T. Chumak, J. Popelar, J. Syka, J. Laco, J. Dedková, G. Dayanithi, S. Filip,
- 520 9_
- $a Canal wall down mastoidectomy is one of the most effective treatments for cholesteatoma. However, it results in anatomical changes in the external and middle ear with a negative impact on the patient's quality of life. To provide complete closure of the mastoid cavity and normalize the anatomy of the middle and external ear, we used human multipotent mesenchymal stromal cells (hMSCs), GMP grade, in a guinea pig model. A method for preparing a biomaterial composed of hMSCs, hydroxyapatite, and tissue glue was developed. Animals from the treated group were implanted with biomaterial composed of hydroxyapatite and hMSCs, while animals in the control group received hydroxyapatite alone. When compared to controls, the group implanted with hMSCs showed a significantly higher ratio of new bone formation (p = 0.00174), as well as a significantly higher volume percentage of new immature bone (p = 0.00166). Our results proved a beneficial effect of hMSCs on temporal bone formation and provided a promising tool to improve the quality of life of patients after canal wall down mastoidectomy by hMSC implantation.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a biologické markery $x metabolismus $7 D015415
- 650 _2
- $a modely nemocí na zvířatech $7 D004195
- 650 _2
- $a vnitřní ucho $x patologie $7 D007758
- 650 _2
- $a morčata $7 D006168
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a zánět $x patologie $7 D007249
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 12
- $a transplantace mezenchymálních kmenových buněk $7 D045164
- 650 _2
- $a mezenchymální kmenové buňky $x cytologie $7 D059630
- 650 _2
- $a multipotentní kmenové buňky $x cytologie $7 D039902
- 650 12
- $a pooperační péče $7 D011182
- 650 _2
- $a spánková kost $x diagnostické zobrazování $x patologie $x chirurgie $7 D013701
- 650 _2
- $a počítačová rentgenová tomografie $7 D014057
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Chrobok, Viktor
- 700 1_
- $a Kalfert, David
- 700 1_
- $a Koci, Zuzana
- 700 1_
- $a Sykova, Eva
- 700 1_
- $a Chumak, Tetyana
- 700 1_
- $a Popelar, Jiri
- 700 1_
- $a Syka, Josef
- 700 1_
- $a Laco, Jan
- 700 1_
- $a Dedková, Jana
- 700 1_
- $a Dayanithi, Govindan
- 700 1_
- $a Filip, Stanislav
- 773 0_
- $w MED00001075 $t Cell transplantation $x 1555-3892 $g Roč. 25, č. 7 (2016), s. 1405-14
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/26497735 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20170413 $b ABA008
- 991 __
- $a 20170427111505 $b ABA008
- 999 __
- $a ok $b bmc $g 1200701 $s 975014
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 25 $c 7 $d 1405-14 $e 20151022 $i 1555-3892 $m Cell transplantation $n Cell Transplant $x MED00001075
- LZP __
- $a Pubmed-20170413
